A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Emerging therapies, including inhaled and targeted treatments, could reshape care for progressive pulmonary fibrosis and address unmet patient needs.

Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane ...

Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential ...

Lung transplantation is the only curative treatment for IPF, but most patients are ineligible, necessitating focus on slowing disease progression. Nintedanib is recommended for PPF, while pirfenidone ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled ...

With receipt of inhaled treprostinil for 52 weeks, adults with idiopathic pulmonary fibrosis had less FVC decline compared ...

Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression “Completing enrollment in this trial brings us one step ...

Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Further, open label extension data published in 2023 showed ...